A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

NCT02696148 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and side effects of the medication liraglutide in children aged 7 to 11 who are obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 24 people

Who can join Ages 7–11 · all sexes

Timeline Started 2016-03 · est. completion 2017-04

Where 9 sites · United States

What this study is testing ClinicalTrials.gov NCT02696148 ↗

Description as written by the study sponsor.

This trial is conducted in the United States of America. The aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of liraglutide in obese children aged 7 to 11 years

Treatments tested

liraglutide Drug

For subcutaneous (s.c., under the skin) injection once daily.
placebo Drug

For subcutaneous (s.c., under the skin) injection once daily.

Main thing measured	Number of treatment emergent adverse events
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02696148 ↗